Latest Commercial Rollouts News

BCAL Diagnostics has partnered with Sonic Healthcare Australia to broaden access to its innovative blood-based breast cancer test, BREASTEST plus™, across Sydney. This move formalizes a commercial rollout following successful trials and aims to improve early detection for women with dense breast tissue.

Decidr AI Industries has locked in a $3.9 million underwriting agreement with Morgans Corporate Limited to back the exercise of listed options expiring this month, providing crucial funding ahead of its DecidrOS Beta release.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

EBR Systems has secured FDA approval for its pioneering leadless WiSE CRT System and obtained key Medicare reimbursement endorsements, setting the stage for its commercial rollout. The company also completed a significant capital raise to support its market expansion.

HeraMED Limited has raised $1.98 million through a discounted share placement to fund its digital maternity care platform's commercial growth across the US, Australia, and Europe.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.